{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:22:27Z","timestamp":1787066547081,"version":"build-2736575974"},"reference-count":28,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Paediatric and Neonatal Pain"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We aimed\u00a0to compare the outcomes of pharmacotherapy with either buprenorphine or methadone in infants treated for neonatal abstinence syndrome (NAS) secondary to intrauterine exposure to methadone. This is a multi\u2010center, retrospective cohort study to assess length of treatment (LOT), hospital length of stay (LOS), and cumulative opioid exposure between infants treated with either methadone or buprenorphine for NAS secondary to in utero exposure to methadone. Infants delivered at a gestational age \u226535\u00a0weeks and a maternal history of opioid\u2010use disorder and\/or urine drug screen positive for methadone, and postnatal pharmacotherapy for NAS with either buprenorphine or methadone as first\u2010line opioid replacement therapy, were eligible. Median LOT, LOS, and cumulative opioid exposure were compared between buprenorphine\u2010 and methadone\u2010treated infants. A total of 156 infants (48 treated with buprenorphine and 108 with methadone) were identified. The median LOT and LOS for buprenorphine\u2010treated infants was 8 and 13\u00a0days compared with 15 and 20\u00a0days for methadone\u2010treated infants, respectively,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0&lt;\u00a0.001 for both outcomes. Median cumulative opioid dose in morphine equivalents was 0.6\u00a0mg\/kg for buprenorphine\u2010treated infants vs 1.05\u00a0mg\/kg for methadone\u2010treated infants,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0&lt;\u00a0.001. No adverse effects were noted among either group. Of infants treated with buprenorphine, 34 (71%) required the addition of adjunctive pharmacotherapy during the NICU stay, compared with 31 (32%) in the methadone\u2010treated group,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a0.0008. However, significantly fewer infants treated with buprenorphine required continuation of therapy beyond discharge as compared with those treated with methadone. The difference is most likely a reflection of the protocols used by the sites. In infants that required pharmacotherapy for NAS secondary to intrauterine exposure to methadone, treatment with buprenorphine, compared with methadone therapy, was associated with better outcomes. If confirmed with prospective data, buprenorphine could be considered first\u2010line therapy for the two medication\u2010assisted treatment\u00a0regimens recommended by the American College of Obstetricians and Gynecologists.\n                  <\/jats:p>","DOI":"10.1002\/pne2.12008","type":"journal-article","created":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T08:42:11Z","timestamp":1572597731000},"page":"33-38","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Buprenorphine pharmacotherapy for the management of neonatal abstinence syndrome in methadone\u2010exposed neonates"],"prefix":"10.1002","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7901-8649","authenticated-orcid":false,"given":"Afshin A.","family":"Taleghani","sequence":"first","affiliation":[{"name":"University of Cincinnati Medical Center Cincinnati Ohio"},{"name":"James L. Winkle College of Pharmacy University of Cincinnati Cincinnati Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara T.","family":"Isemann","sequence":"additional","affiliation":[{"name":"University of Cincinnati Medical Center Cincinnati Ohio"},{"name":"James L. Winkle College of Pharmacy University of Cincinnati Cincinnati Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ward R.","family":"Rice","sequence":"additional","affiliation":[{"name":"Department of Pediatrics University of Cincinnati Cincinnati Ohio"},{"name":"Division of Neonatology and Pulmonary Biology Cincinnati Children\u2019s Hospital Medical Center Cincinnati Ohio"},{"name":"St. Elizabeth Medical Center Edgewood Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura P.","family":"Ward","sequence":"additional","affiliation":[{"name":"Department of Pediatrics University of Cincinnati Cincinnati Ohio"},{"name":"Division of Neonatology and Pulmonary Biology Cincinnati Children\u2019s Hospital Medical Center Cincinnati Ohio"},{"name":"Mercy Hospital Anderson Cincinnati Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy E.","family":"Wedig","sequence":"additional","affiliation":[{"name":"Department of Pediatrics University of Cincinnati Cincinnati Ohio"},{"name":"Division of Neonatology and Pulmonary Biology Cincinnati Children\u2019s Hospital Medical Center Cincinnati Ohio"},{"name":"Good Samaritan Hospital Cincinnati Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry T.","family":"Akinbi","sequence":"additional","affiliation":[{"name":"University of Cincinnati Medical Center Cincinnati Ohio"},{"name":"Department of Pediatrics University of Cincinnati Cincinnati Ohio"},{"name":"Division of Neonatology and Pulmonary Biology Cincinnati Children\u2019s Hospital Medical Center Cincinnati Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,11]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-3520"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2012.04038.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j3616"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/jp.2015.36"},{"key":"e_1_2_7_6_1","unstructured":"Centers for Disease Control and Prevention.The problem of neonatal abstinence syndrome. Public Health Grand Rounds. Accessed September 18 2017."},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1542\/hpeds.2015-0024"},{"key":"e_1_2_7_8_1","unstructured":"Medication\u2010assisted treatment is the recommended therapy during pregnancy.https:\/\/www.acog.org\/About-ACOG\/News-Room\/News-Releases\/2017\/Medication-assisted-Treatment-Remains-the-Recommended-Therapy\u2013for-Pregnant-Women. Accessed March 14 2018."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2011-3212"},{"issue":"10","key":"e_1_2_7_10_1","first-page":"CD002053","article-title":"Sedatives for opiate withdrawal in newborn infants","author":"Osborn DA","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2014.05.010"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jp.7211427"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1608634"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-4036"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2015.08.032"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614835"},{"issue":"1","key":"e_1_2_7_17_1","first-page":"141","article-title":"Neonatal abstinence syndrome: assessment and management","volume":"2","author":"Finnegan LP","year":"1975","journal-title":"Addict Dis"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"e_1_2_7_19_1","unstructured":"Centers for Disease Control and Prevention.Opioid oral morphine milligram equivalent (MME) conversion factors.https:\/\/www.cms.gov\/Medicare\/Prescription-Drug-Coverage\/PrescriptionDrugCovContra\/Downloads\/Opioid-Morphine-EQ-Conversion-Factors-Aug-2017.pdf. Accessed May 31 2018."},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-3524"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.2174\/1570159043359477"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2010.03170.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-2377"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/jp.2014.114"},{"key":"e_1_2_7_25_1","unstructured":"US Government Accountability Office.Prenatal drug use and newborn health: federal efforts need better coordination and planning.http:\/\/www.gao.gov\/assets\/670\/668385.pdf. Accessed September 18 2017."},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2012.04039.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/jp.2017.157"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1005359"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2018.1307"}],"container-title":["Paediatric and Neonatal Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpne2.12008","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pne2.12008","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pne2.12008","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pne2.12008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T13:05:52Z","timestamp":1694091952000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pne2.12008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1002\/pne2.12008"],"URL":"https:\/\/doi.org\/10.1002\/pne2.12008","archive":["Portico"],"relation":{},"ISSN":["2637-3807","2637-3807"],"issn-type":[{"value":"2637-3807","type":"print"},{"value":"2637-3807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"2019-03-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}